Insight Molecular Diagnostics (IMDX) Earnings Date & Reports

Key Takeaways

• Insight Molecular Diagnostics (IMDX) is scheduled to report third quarter 2026 results after the market close on Monday, November 16, 2026.
• Consensus estimates point to a loss of roughly $0.23 to $0.24 per share on revenue near $249,000, reflecting the company's early commercialization stage.
• IMDX remains essentially pre-revenue as it awaits U.S. Food and Drug Administration (FDA) authorization for its flagship GraftAssureDx transplant test.
• Investors will focus on the FDA review timeline, cash position, and quarterly cash burn rather than headline revenue.
• In the prior quarter, IMDX posted revenue of $239,000 and a net loss of $11.3 million, with a non-GAAP net loss of $0.23 per share.
• For deeper context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• You can also explore Trending AI Robots for additional market insights and automated trading signals.

Earnings Context and Why It Matters

For Insight Molecular Diagnostics, quarterly earnings are less about revenue and more about regulatory milestones. The company is betting its future on GraftAssure, a family of transplant-rejection tests that measure donor-derived cell-free DNA (dd-cfDNA), a blood-based biomarker used to assess organ rejection. The pivotal catalyst is FDA marketing authorization for GraftAssureDx, its in vitro diagnostic (IVD) kit. Management has said it does not expect material kit revenue until that authorization arrives, making the third quarter report a key checkpoint on cash runway, research and development (R&D) spending, and go-to-market readiness ahead of a potential 2026 commercial launch.

Earnings Expectations

Analysts expect IMDX to remain loss-making. Consensus estimates call for a net loss of approximately $0.23 to $0.24 per share, with revenue projected near $249,000, largely from laboratory services. By comparison, the company reported a non-GAAP net loss of $0.23 per share on $239,000 of revenue in the second quarter of 2026, and a loss of $0.34 per share on about $260,000 of revenue in the same quarter a year earlier.

Historical price reactions around IMDX reports have been volatile. The stock fell roughly 7% the day after the August 2026 report, rose about 26% following the May 2026 release, and declined about 13% after the March 2026 update. Given the company's pre-revenue status, investors will likely weigh management's commentary on the FDA review, cash burn guidance, and any early signs of commercial traction in the U.S. and Europe more heavily than the raw financial figures.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like IMDX, it offers a structured way to surface comparable opportunities across the diagnostics and healthcare landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report is cautious but watchful. IMDX shares have experienced significant volatility over the past year, and the stock carries a beta well above the market average, meaning it tends to move more sharply than the broader market. With the company still pre-revenue in its core kitted-test business, the market is primarily pricing the probability of FDA authorization for GraftAssureDx. Key risks include potential regulatory delays, continued cash burn, dilution from past and possible future capital raises, and slower-than-expected adoption even after approval. The stock's reaction will likely hinge less on the loss-per-share figure and more on any forward-looking commentary about the FDA process.

Forward Outlook and Key Factors to Monitor

Following the report, the most important item to watch is the status of the FDA submission for GraftAssureDx, which targets kidney transplant monitoring first. Management has indicated it expects FDA marketing authorization later in 2026, and any update on that timeline will likely be the single biggest driver of investor sentiment.

Cash runway is the second major factor. IMDX ended the first quarter of 2026 with about $29.4 million in cash, cash equivalents, and restricted cash, supported by a $26 million registered direct offering. The company has guided for elevated cash burn early in the year, with quarterly burn expected to decline as heavy FDA-submission-related R&D spending rolls off. Investors should monitor whether the company reaffirms or adjusts that trajectory.

Finally, watch for early commercialization signals, including research-use-only (RUO) GraftAssureIQ kit sales outside the U.S. and any indications of initial U.S. customer interest ahead of potential authorization. Long term, the company is targeting a gross margin of 70% or higher, though it does not expect to reach that level in the first six to twelve months after commercialization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations